Perspective Therapeutics, Inc. announced the presentation of encouraging early clinical results from an open-label, single-arm, investigator-initiated study investigating the safety and efficacy of [212Pb]VMT-a-NET, ?a targeted alpha therapy (TAT), in patients with metastatic neuroendocrine tumors (NETs) and medullary thyroid carcinomas. The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9, 2023 to September 13, 2023. Highlights of the presented results include: Ten patients who failed at least 1 prior line of standard of care therapy have received [212Pb]VMT-a-NET therapy to date, with initial responses observed in 7 of 9 evaluable patients.

Responses were observed across both peptide receptor radionuclide therapy (PRRT)-naïve and PRRT-refractory disease. Of the 10 patients enrolled in the study, 3 presented with gastrointestinal NETs, 5 presented with pancreatic NETs, and 2 presented with medullary thyroid carcinoma. Four patients (1 with gastro-intestinal NETs; 3 with pancreatic NETs) were previously treated with [177Lu]DOTATATE PRRT, one of which also received 3 prior administrations of [225Ac]DOTATATE.

Improvements in patients? symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-a-NET doses. No significant renal or hepatic function adverse events have been observed to date?.

Most adverse events were mild and included Grade 1 anemias, alopecia, and fatigue, which usually resolved within 1 week of [212Pb]VMT-a-NET administration. Two patients experienced serious adverse events (SAEs) that were deemed unrelated to [212Pb]VMT-a-NET treatment. One patient who developed myelodysplastic syndromes (MDS) discontinued treatment and the other patient, who was heavily pre-treated, died (patient was deemed not evaluable).